Thank you, Mr. Chair.
There is an important principle of transparency around the conditions of an authorization, which is certainly very important in the regulatory cycle.
If a drug is approved and there are conditions to conduct further studies on market, there is an interest by all in knowing what progress has been made. There is an intention to bring that into regulation, but we can do that as a matter of obligation under the regulations without ensuring it through further language here. It's already something the GIC can make a regulation about. The intention to have the element of transparency is very important.